| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Mertuzumab | Phase 3 Clinical | Institute Of Medicine Fourth Military Medical University, Jiangsu Pacific Minok Biopharmaceutical Co., Ltd. | Carcinoma, Non-Small-Cell Lung; Coronavirus Disease 2019 (COVID-19) | Details | |
| Meplazumab | HI6H8 | Phase 3 Clinical | Institute Of Medicine Fourth Military Medical University, Jiangsu Pacific Minok Biopharmaceutical Co., Ltd. | Coronavirus Disease 2019 (COVID-19); Malaria; Malaria, Falciparum; Post-Acute COVID-19 Syndrome | Details |
| humanized ADCC cHAb18 antibody (Pacific Meinuoke/Fourth Military Medical University) | Phase 1 Clinical | Air Force Medical University | Carcinoma, Non-Small-Cell Lung | Details | |
| CD147-CAR T cell therapy (Peking University People's Hospital) | Phase 1 Clinical | Peking University People'S Hospital | Lymphoma, T-Cell | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Iodine[131I] Metuximab | Approved | Chengdu Huasun Biotechnology Co Ltd | Licartin, 利卡汀 | Mainland China | Carcinoma, Hepatocellular | Chengdu Huasun Biotechnology Co Ltd | 2006-10-12 | Carcinoma, Hepatocellular | Details |